Analysis

Description: This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

Description:

Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

Description:

Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

Description: This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

Description:

Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

Description:

The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

Description:

In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.

Description:

This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.

Description:

This article looks at the use of biotechnology, obstacles to commercialization and information sources on biotechnology.

Description:

Biotechnology firms are generally flexible and innovative in their approaches to survival and growth in Canada and also on the world stage. Read an overview of some of the business strategies and practices used by biotechnology firms to conduct research and development and for some, commercialization of their products.

Description: This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

Description:

Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

Description:

Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

Description: This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

Description:

Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

Description:

The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

Description:

In 2001, there were 375 biotechnology innovator firms in Canada, an increase of just under 5% from the 358 firms in 1999. Analysis beyond these overall statistics discloses a dynamic churning that is occurring among sectors, provinces and size groups.

Description:

This is the final of three papers providing data and an overview of the results of the Biotechnology Use and Development Survey - 1999. Readers are encouraged to use the data. The next edition of the Biotechnology Use and Development Survey - 2001 is expected to be administered in the spring of 2002 with results available early in 2003.

Description:

This article looks at the use of biotechnology, obstacles to commercialization and information sources on biotechnology.

Description:

Biotechnology firms are generally flexible and innovative in their approaches to survival and growth in Canada and also on the world stage. Read an overview of some of the business strategies and practices used by biotechnology firms to conduct research and development and for some, commercialization of their products.